Mirati Announces Executive Management Changes

Mirati Therapeutics has announced changes to their executive management team, effective immediately. Mirati continues to accelerate the development of the KRAS and sitravatinib programs through registrational trials and prepare for commercialization which includes growing their world class executive team.

Daniel R. Faga was appointed as Executive Vice President, Chief Operating Officer and will report directly to Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer. He will be responsible for a broad range of operational areas including but not limited to corporate strategy, finance, legal, program management and investor relations & corporate affairs. Faga is a seasoned executive with almost 20 years of biopharma and investment banking experience in the life sciences sector. He also has extensive experience in developing and executing biopharma growth strategies with expertise in corporate strategy, mergers and acquisitions, and partnering on more than $50 billion in biopharma transactions. He was formerly the Chief Business Officer at Spark Therapeutics, Inc., a broad operating position he held since 2016. Prior to joining Spark Therapeutics, Faga was a managing director at Centerview Partners, from 2009 – 2016, where he served as a founding member of their healthcare advisory practice. Prior to Centerview Partners, Faga held additional investment banking and management consulting roles advising biotech and pharmaceutical companies. Dan earned a B.S. in Engineering from Cornell University and an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania.

Benjamin J. Hickey was appointed as Executive Vice President, Chief Commercial Officer and will report directly to Dr. Baum. His responsibilities will include all aspects of global launch readiness and brand strategy including, sales and marketing, pricing and access, medical affairs, forecasting and analytics, portfolio planning and patient advocacy. Hickey has had a successful career in the pharmaceutical industry with commercial and general management roles in the U.S. and Europe and brings 19 years of experience to this new role at Mirati. During his career he has built strong commercial organizations and led strategic marketing development and oversight of numerous successful global product launches. In his most recent position, Hickey was Senior Vice President and Chief Commercial Officer at Halozyme Therapeutics, Inc. where he was responsible for the global commercial strategy for the Company's oncology portfolio. Prior to that, Hickey held roles of increasing responsibility at Bristol-Myers Squibb over a 17-year period, including serving as Vice President Marketing, Immuno-Oncology where he led the commercialization of YERVOY® and oversaw the launch preparedness of OPDIVO® across more than fourteen indications in the U.S. and Europe. He received his B.S. in Management and his M.B.A from St. John's University in New York.

Vickie S. Reed was promoted to Senior Vice President, Finance and Chief Accounting Officer. Reed has been with Mirati for six years and has worked in roles of increasing responsibility during that time. She has over 20 years of biotech experience, where she built a track record of proven leadership and building high performing finance teams. She has expertise in Sarbanes-Oxley Act compliance, resolution of complex accounting issues and process improvement to maximize corporate finance performance. Reed is a Certified Public Accountant (Colorado) and received a B.S. in Accounting from the University of Colorado Denver.

Jessica M. Corson was promoted to Vice President, Business Development. Jessica has been with Mirati for seven years and has worked in roles of increasing responsibility. She brings over 15 years of experience in biotech including buy and sell side product licensing, mergers and acquisitions, diagnostic collaborations, R&D alliances and public financings, encompassing transactions that collectively value over $10 billion. Corson holds a B.S. in Biology from the University of California, San Diego and an M.B.A from the UCLA Anderson School of Management.

"Mirati is entering the next stage of drug development as our novel therapies, which we believe will address critical unmet needs for cancer patients. I am very pleased to welcome Dan and Ben to Mirati and believe that they will be instrumental in our success as we enter a pivotal phase in the Company's growth and move toward becoming a global, commercial-ready biopharmaceutical company. Dan brings strong leadership, business and operational experience in executing long-range strategic plans to the team while Ben will build our commercial capability and help us bring much needed therapies like sitravatinib to patients whose tumors no longer respond to immunotherapy and to patients who have the potential to benefit from our other programs, that target specific types of KRAS mutations where no approved targeted therapies are available. Both are accomplished executives with proven expertise who will be instrumental as we continue to build our pipeline of first- and best-in-class programs," said Dr. Baum.

"I'd also like to congratulate Vickie Reed and Jessica Corson on their promotion to senior leadership positions. They have been important to Mirati's development and embody the culture and values that have led to our success," said Dr. Baum. "Chris LeMasters, Chief Business Officer and Jamie Donadio, Chief Financial Officer, have left the Company to pursue other opportunities. Mr. Donadio will remain at Mirati in a temporary consulting role as we complete these transitions. The Board and I recognize their valuable contributions to Mirati and wish them well in their future endeavors."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.